
    
      OBJECTIVES: I. Determine the efficacy and safety of rituximab and ibritumomab tiuxetan
      radioimmunotherapy in patients with refractory or relapsed, low-grade, follicular, or
      transformed B-cell non-Hodgkin's lymphoma.

      OUTLINE: This is a multicenter study. Patients receive rituximab IV on days 1 and 8
      immediately followed by IDEC-In2B8 IV over 10 minutes on day 1. Patients also receive
      ibritumomab tiuxetan IV over 10 minutes on day 8. Patients are followed every 3 months for 2
      years and then every 6 months for 2 years.

      PROJECTED ACCRUAL: Approximately 400 patients will be accrued for this study.
    
  